Drug intelligence / Profile preview

ANT-SM

Development stage: Phase 1
Lead developer: Anterogen
Modality: Stem Cell Therapies → Cell Therapies
Administration: Local Injection

Overview

ANT-SM is an autologous cultured adipose-derived stem cell therapy developed by Anterogen Co., Ltd. for the treatment of fecal incontinence. As an autologous therapy, it is expected to avoid immune responses, addressing a common problem with other therapeutic methods such as surgical operations or material injections. The treatment involves the injection of these stem cells into the anal sphincter.

Other names: Autologous Cultured Adipose-derived Stem Cell

Beyond the preview

Go deeper on ANT-SM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-SM.

Explore the full profile